// App-Quantinova.ai

4693 : Myeloablative Cord Blood Transplantation Yields Excellent Disease Free Survival in Patients with Acute Lymphoblastic Leukemia

Researchers

Presenter

  • David Charles Keahi Oliver

Principal Investigators

  • Ryan D Cassaday

  • Ralph P Ermoian

  • Ann Dahlberg

  • Colleen Delaney

  • Filippo Milano

Medical Centers

  • Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA

  • Departments of Pediatrics and Immunology, University of Washington School of Medicine, Seattle, WA

  • Seattle Cancer Care Alliance, Seattle, WA

  • Hematology / Medicine, University of Washington School of Medicine, Seattle, WA

  • Division of Hematology, University of Washington School of Medicine, Seattle, WA

Locations

  • United States

Companies

  • N/A

Study Components

Therapeutic Area

  • Autoimmune (AI)

Disease

  • Acute lymphoblastic leukemia

  • Graft-versus-host disease

Biomarkers

  • Breakpoint Cluster Region

  • Hematocrit

  • Major Histocompatibility Complex, Class I, A

  • Major Histocompatibility Complex, Class I, B

  • Major histocompatibility complex, class II, DR beta 1

Drug/Treatment

  • Cyclosporine eent

  • fludarabine tablet

  • Ovastat

  • Cytoxan oral and injection

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • Interim

Copyright © 2026. QuantiNova All rights reserved